Biotech Values

[DewDiligence]

Clinical / Regulatory / Litigation Calendar

[Please keep these entries up to date! See
the updating procedure at the end of this post.
Items that are out of date will be removed.]

NOTE: ANYONE MAY UPDATE THIS FILE


Edits: ABT AGN.


ABT – Split into two companies (ABBV and “new” ABT) 1/1/13.
ABT – Full presentation of AVIATOR HCV trial at AASLD.
ABT – ‘Absorb’ bioresorbable stent: US launch possible in 2013 (pending clinical results); launched in 30 countries including EU 9/25/12.

ACHN – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78298188 .

AGN – Latisse for androgenetic alopecia: phase-2 data in men and women at unspecified medical conference in 2013.
AGN – BLA for Botox in idiopathic OAB: PDUFA date 1H13.
AGN – PMA for Juvederm Voluma: PDUFA date 1H13.
AGN – Phase-2 DARPin data in AMD: 2H13.

AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2012-2013 pending results of phase-3 trial in breast cancer.

AMRN – Vascepa (f/k/a AMR101) approved by FDA 7/26/12; decision on NCE status pending.

BIIB – BG-12 for MS: PFUFA date 3/28/13 (extended 3m); MAA pending—no further info available.

BMY – Eliquis in AF/stroke prevention: PDUFDA date (on resubmitted NDA) 3/17/13; approved by CHMP 9/21/12 (formal EU approval Nov/Dec).
BMY – Eliquis in VTE prevention: approved in EU 3/18/11—commercial launch in most countries by end of 2012; pursuit of this indication in US appears to be dead (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=58061618 ).

BMY – Yervoy phase-3 in 2nd-line CRPC: data mid 2013.

EXEL – Cabozantinib for MTC PDUFA date 11/29/12 (no ODAC).

GILD – HCV program (GS-7977, GS-5885): see description of various trials and dates in http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77952062 .
GILD – “Standalone” Evitegravir: NDA submitted 6/27/12, awaiting decision on priority review.
GILD – “Standalone” Cobicstat NDA submitted 6/28/12; MAA submitted 5/23/12.
GILD – GS-7340/’Quad Prime’: Two phase-2 studies ongoing with data in late 2012 or 2013—one tests Quad Prime vs Atripa and one tests Quad Prime vs Prezista + Cobicstat + Truvada.

IDIX – IDX719 (NS5A inhibitor): 3-day PoC phase-1b monotherapy data reported 6/20/12; NVS now has exclusive option to license IDX719 with a decision expected in about 3 months. (IDX184 and IDX19368 are on FDA clinical hold.)

ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.

JNJ – Xarelto NDA for VTE treatment/secondary prevention: on or about 11/2/12; Xarelto NDA in PCI sub-indication of ACS resubmitted 9/7/12.
JNJ – Zytiga PDUFA for sNDA in pre-chemo CRPC 4/14/13.

LGND - Promacta for HCV: PDUFA date 11/30/12 (priority review); MAA submitted 5/30/12.
LGND - SCH527123 (MRK) CXCR2 antagonist p2 COPD is enrolled, data early 2012

MNTA – See http://investorshub.advfn.com/boards/read_msg.aspx?message_id=79377345

NAVB – Lymphoseek CRL issued due to CMC issues 9/10/12.

PFE – Tofacitinib PDUFA date 11/21/12.
PFE – Bosutinib in CML: EU decision any day (MAA accepted for review 8/17/11); FDA approved 9/4/12.
PFE – Eliquis: see BMY.

SNY – Aubagio for RRMS: MAA accepted for review 2/23/12; (approved by FDA 9/12/12). Lemtrada for RRMS: RTF issued 8/27/12; resubmission pending.

TEVA – Thrice-weekly formulation of Copaxone: timing of NDA unclear according to 6/14/12 PR announcing positive top-line results from GALA study.

VRTX – Phase-2b testing multiple (non-response-guided) protocols for Incivek + VX-222 + ribavirin in treatment-naïve genotype-1 to start 3Q12. (Data on no-IFN arms of ZENITH study reported 2/23/12.)

--
Procedure for Updating Calendar

When adding or modifying entries, please follow these steps:

1. Copy the complete text from the old calendar.

2. Make your additions or modifications, inserting new items in alphabetical order.

3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).